Sarepta Therapeutics Company Insiders

SRPT Stock  USD 110.50  0.36  0.32%   
Slightly above 89 percent of Sarepta Therapeutics' insiders are activelly selling. The analysis of the overall insider sentiment regarding Sarepta Therapeutics suggests that a very large number of insiders are panicking. Sarepta Therapeutics employs about 1.3 K people. The company is managed by 13 executives with a total tenure of roughly 3066 years, averaging almost 235.0 years of service per executive, having 101.08 employees per reported executive.

Sarepta Therapeutics' Insider Buying Vs Selling

11

 
Selling
 
Buying

Latest Trades

2024-08-30Ian Michael EstepanDisposed 5985 @ 137.36View
2024-08-16Michael Andrew ChambersAcquired 37038 @ 133.8View
2024-06-25Ryan Edward BrownDisposed 38957 @ 161.61View
2024-06-24Bilal ArifDisposed 7859 @ 163.08View
2024-05-02Dallan MurrayDisposed 3635 @ 140View
2024-03-11Kathryn Jean BoorDisposed 761 @ 122.93View
2024-03-08Hans Lennart Rudolf WigzellDisposed 15000 @ 123.25View
2024-03-05Stephen MayoDisposed 3135 @ 122.96View
2024-03-01Ian Michael EstepanDisposed 1200 @ 128.3View
Monitoring Sarepta Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.

Sarepta Therapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Sarepta Therapeutics' future performance. Based on our forecasts, it is anticipated that Sarepta will maintain a workforce of slightly above 1310 employees by December 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Sarepta Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of 0.0151 % which means that it generated a profit of $0.0151 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1227 %, meaning that it created $0.1227 on every $100 dollars invested by stockholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Sarepta Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 3.4 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 39 M in 2024.
Common Stock Shares Outstanding is likely to gain to about 97 M in 2024, despite the fact that Net Loss is likely to grow to (601.5 M).

Sarepta Therapeutics Workforce Comparison

Sarepta Therapeutics is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 4,891. Sarepta Therapeutics totals roughly 1,314 in number of employees claiming about 27% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.07 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.05 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.05.

Sarepta Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sarepta Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sarepta Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Sarepta Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-09-01
2.0
6
3
 61,322 
 21,731 
2024-06-01
0.5769
15
26
 108,000 
 120,820 
2024-03-01
0.5758
19
33
 86,496 
 119,149 
2023-12-01
2.3333
7
3
 90,225 
 23,190 
2023-09-01
3.5
7
2
 83,532 
 30,000 
2023-03-01
1.2222
22
18
 159,460 
 63,585 
2022-12-01
0.5
2
4
 50,000 
 25,069 
2022-06-01
2.0
2
1
 16,658 
 54.00 
2022-03-01
2.3333
21
9
 313,535 
 64,219 
2021-12-01
2.3333
7
3
 87,303 
 30,529 
2021-03-01
1.75
28
16
 499,464 
 101,540 
2020-12-01
0.625
5
8
 53,207 
 42,591 
2020-09-01
0.5
5
10
 14,931 
 53,671 
2020-06-01
0.3333
5
15
 110,122 
 270,844 
2020-03-01
3.5714
25
7
 230,760 
 102,337 
2019-12-01
0.7143
20
28
 350,945 
 580,934 
2019-09-01
1.7778
16
9
 150,506 
 214,754 
2019-06-01
0.4
2
5
 22,000 
 65,505 
2019-03-01
1.0968
34
31
 420,406 
 419,372 
2018-12-01
1.0
11
11
 143,386 
 242,270 
2018-09-01
0.6364
7
11
 99,782 
 154,845 
2018-06-01
0.6
6
10
 133,276 
 139,552 
2018-03-01
1.087
25
23
 428,690 
 25,187 
2017-12-01
0.7143
5
7
 82,705 
 56,334 
2017-09-01
0.6667
20
30
 318,711 
 248,289 
2017-06-01
2.0
4
2
 3,775,000 
 4,349 
2017-03-01
2.0
22
11
 300,100 
 72,035 
2016-12-01
0.7143
5
7
 36,000 
 70,348 
2016-09-01
0.52
13
25
 165,861 
 252,762 
2016-03-01
5.2857
37
7
 608,229 
 53,005 
2015-09-01
0.5
1
2
 7,692 
 3,000 
2015-06-01
3.0
3
1
 130,275 
 0.00 
2015-03-01
6.5
26
4
 1,014,600 
 39,500 
2014-09-01
1.0
1
1
 23,450 
 23,450 
2014-03-01
5.75
23
4
 778,500 
 145,000 
2013-12-01
1.0
1
1
 10,000 
 15,933 
2013-09-01
2.5
5
2
 21,056 
 11,112 
2013-06-01
2.1818
24
11
 691,000 
 351,625 
2012-09-01
9.5
19
2
 407,498 
 33,000 
2011-09-01
2.5
5
2
 720,000 
 24,999 
2011-03-01
3.0
3
1
 4,450,000 
 40,000 
2010-09-01
0.3167
19
60
 2,126,000 
 3,234,000 
2010-06-01
9.0
27
3
 639,107 
 51,338 
2010-03-01
1.5455
17
11
 1,614,000 
 4,850,073 
2009-09-01
2.0
4
2
 1,280,000 
 471,034 
2009-06-01
5.6667
17
3
 625,000 
 500.00 
2009-03-01
21.0
21
1
 1,751,902 
 2,682 
2008-09-01
0.5
2
4
 356,582 
 110,000 
2008-06-01
1.6
8
5
 293,000 
 1,884,721 
2008-03-01
4.7143
33
7
 4,429,159 
 277,500 
2007-12-01
0.2222
2
9
 66,000 
 10,000 
2007-06-01
2.0
16
8
 1,240,000 
 614,807 

Sarepta Therapeutics Notable Stakeholders

A Sarepta Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sarepta Therapeutics often face trade-offs trying to please all of them. Sarepta Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sarepta Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Douglas EsqCEO PresidentProfile
Ian EstepanExecutive CFOProfile
Ryan JDGeneral VPProfile
Will TiltonHead VPProfile
William CiambroneEx OperationsProfile
Dallan MurrayExecutive OfficerProfile
Louise RodinoKlapacChief VPProfile
Alison NasisiExecutive OfficerProfile
Bilal ArifExecutive OfficerProfile
Diane BerryExecutive OfficerProfile
Ryan BrownGen VPProfile
Mary JenkinsSr RelationsProfile
Francesca NolanExecutive CommunicationsProfile

About Sarepta Therapeutics Management Performance

The success or failure of an entity such as Sarepta Therapeutics often depends on how effective the management is. Sarepta Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sarepta management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sarepta management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.17)(0.17)
Return On Capital Employed(0.10)(0.11)
Return On Assets(0.16)(0.17)
Return On Equity(0.62)(0.65)
Please note, the imprecision that can be found in Sarepta Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sarepta Therapeutics. Check Sarepta Therapeutics' Beneish M Score to see the likelihood of Sarepta Therapeutics' management manipulating its earnings.

Sarepta Therapeutics Workforce Analysis

Traditionally, organizations such as Sarepta Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sarepta Therapeutics within its industry.

Sarepta Therapeutics Manpower Efficiency

Return on Sarepta Therapeutics Manpower

Revenue Per Employee946.2K
Revenue Per Executive95.6M
Net Loss Per Employee407.9K
Net Loss Per Executive41.2M
Working Capital Per Employee1.5M
Working Capital Per Executive148.1M

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.